drugset / Trial / NCT00595140
Acute Application of Pegvisomant and Octreotide in Acromegaly
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of the study is to investigate the efficacy of an acute additional application of the somatostatin analogue octreotide 100µg s.c. or the dopamine agonist cabergoline 0.5mg p.o. to the receptor antagonist pegvisomant during a 6 or 9 hour profile on reducing endogenous growth hormone in patients with acromegaly on stable pegvisomant therapy.
Timeline
- Start
- 2008-01
- Primary completion
- 2008-03
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cabergoline | Small molecule | 0.5 mg | Oral |
| Comparator | Octreotide | Peptide | 100 ug | Subcutaneous |
| Comparator | Pegvisomant | Protein / enzyme biologic | — | — |